The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis
Open accessAbstract
Phase 3 trial of seladelpar in PBC with inadequate response or unacceptable side effects with UDCA.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Overall, seladelpar was well tolerated.”
From Second-Line Therapies in Primary Biliary Cholangitis: A Comparative Review of Obeticholic Acid, Fibrates, Seladelpar, and Elafibranor (2025) · cites this paper as [47]
In the citing paper
“As detailed earlier, pruritus was less frequent in seladelpar when compared to placebo.”
From Second-Line Therapies in Primary Biliary Cholangitis: A Comparative Review of Obeticholic Acid, Fibrates, Seladelpar, and Elafibranor (2025) · cites this paper as [47]
In the citing paper
“There were no reported treatment-related deaths [16,23,47].”
From Second-Line Therapies in Primary Biliary Cholangitis: A Comparative Review of Obeticholic Acid, Fibrates, Seladelpar, and Elafibranor (2025) · cites this paper as [47]
In the citing paper
“However, ALT and GGT were significantly decreased with seladelpar which indicates reduced hepatocellular injury [47].”
From Second-Line Therapies in Primary Biliary Cholangitis: A Comparative Review of Obeticholic Acid, Fibrates, Seladelpar, and Elafibranor (2025) · cites this paper as [47]
In the citing paper
“Those on seladelpar 10 mg (n = 49) achieved −3.2 points while patients on placebo (n = 23) achieved −1.7 points (p = 0.005).”
From Second-Line Therapies in Primary Biliary Cholangitis: A Comparative Review of Obeticholic Acid, Fibrates, Seladelpar, and Elafibranor (2025) · cites this paper as [47]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Hirschfield, G. M., Beuers, U., Corpechot, C., Invernizzi, P., Jones, D., Marzioni, M., & Schramm, C. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.03.022 · Cited by 1,480
Self-citationA Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
Nevens, F., Andreone, P., Mazzella, G., Strasser, S. I., Bowlus, C., Invernizzi, P., Drenth, J. P. H., Pockros, P. J., Regula, J., Beuers, U., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1509840 · Cited by 1,131
Self-citationInterleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice
Dillon, S. R., Sprecher, C., Hammond, A., Bilsborough, J., Rosenfeld-Franklin, M., Presnell, S. R., Haugen, H. S., Maurer, M., Harder, B., Johnston, J., et al. (2004) · Nature Immunology · doi:10.1038/ni1084 · Cited by 1,015
Lindor, K. D., Bowlus, C. L., Boyer, J., Levy, C., & Mayo, M. (2019) · Hepatology · doi:10.1002/hep.30145 · Cited by 913
Self-citationAlternative M2 Activation of Kupffer Cells by PPARδ Ameliorates Obesity-Induced Insulin Resistance
Odegaard, J. I., Ricardo-Gonzalez, R. R., Red Eagle, A., Vats, D., Morel, C. R., Goforth, M. H., Subramanian, V., Mukundan, L., Ferrante, A. W., & Chawla, A. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.04.003 · Cited by 847
Parés, A., Caballería, L., & Rodés, J. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.12.029 · Cited by 756
Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis
Corpechot, C., Abenavoli, L., Rabahi, N., Chrétien, Y., Andréani, T., Johanet, C., Chazouillères, O., & Poupon, R. (2008) · Hepatology · doi:10.1002/hep.22428 · Cited by 646
Self-citationA Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis
Corpechot, C., Chazouillères, O., Rousseau, A., Le Gruyer, A., Habersetzer, F., Mathurin, P., Goria, O., Potier, P., Minello, A., Silvain, C., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714519 · Cited by 642
Self-citationThe 5-D itch scale: a new measure of pruritus
Elman, S., Hynan, L. S., Gabriel, V., & Mayo, M. J. (2010) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2009.09586.x · Cited by 540
Self-citationCorpechot, C., Chazouillères, O., & Poupon, R. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.02.031 · Cited by 460
Self-citation
Cited by
Tanaka, A., Ma, X., Takahashi, A., & Vierling, J. M. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01303-5 · Cited by 177
“98,99 The first RCT was the phase 3 study (ELATIVE) of elafibranor, a dual PPAR-α/δ agonist in which patients with an incomplete response to ursodeoxycholic acid were randomly assigned to receive elafibranor 80 mg (n=108) or placebo (n=53) while continuing ursodeo xycholic acid treatment.”
Self-citationFluorine in the Pharmaceutical Industry: FDA‐Approved Fluorine‐Containing Drugs in 2024
Du, Y., Bian, Y., Baecker, D., Dhawan, G., Semghouli, A., Kiss, L., Zhang, W., Sorochinsky, A. E., Soloshonok, V. A., & Han, J. (2025) · Chemistry - A European Journal · doi:10.1002/chem.202500662 · Cited by 136
Trivedi, P. J., Hirschfield, G. M., Adams, D., & Vierling, J. M. (2024) · Gastroenterology · doi:10.1053/j.gastro.2024.01.049 · Cited by 111
Self-citationBile Acid Signaling in Metabolic and Inflammatory Diseases and Drug Development
Li, T., & Chiang, J. Y. L. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.124.000978 · Cited by 90
Assessment of fatigue and its impact in chronic liver disease
Younossi, Z. M., Kremer, A. E., Swain, M. G., Jones, D. E., Bowlus, C. L., Trauner, M., Henry, L. L., & Gerber, L. H. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.04.008 · Cited by 63
Self-citationPrimary sclerosing cholangitis
Manns, M. P., Bergquist, A. M., Karlsen, T. H., Levy, C., Muir, A. J., Ponsioen, C. Y., Trauner, M., Wong, G. L., & Younossi, Z. M. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00600-x · Cited by 80
Self-citationThe history and future of bile acid therapies
Beuers, U. H., Bañales, J. M., Karpen, S. J., Keitel, V., Williamson, C., & Trauner, M. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.06.010 · Cited by 46
Antifibrotic therapies for metabolic dysfunction-associated steatotic liver disease
Schwabe, R. F., Tacke, F., Sugimoto, A., & Friedman, S. L. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101421 · Cited by 70
Novel drugs approved by the EMA, the FDA and the MHRA in 2024: A year in review
Topouzis, S., Papapetropoulos, A., Alexander, S. P. H., Cortese-Krott, M. M., Kendall, D. A., Martemyanov, K. A., Mauro, C., Nagercoil, N., Panettieri, R. A., Patel, H. H., et al. (2025) · British Journal of Pharmacology · doi:10.1111/bph.17458 · Cited by 43
Obeticholic Acid and Other Farnesoid-X-Receptor (FXR) Agonists in the Treatment of Liver Disorders
Fiorucci, S., Urbani, G., Distrutti, E., & Biagioli, M. (2025) · Pharmaceuticals · doi:10.3390/ph18091424 · Cited by 46
“Aside from the beneficial anticholestatic effects, this study also achieved its prespecified secondary endpoint of pruritus improvement [107].”
Primary biliary cholangitis: Personalizing second-line therapies
Levy, C., & Bowlus, C. L. (2024) · Hepatology · doi:10.1097/hep.0000000000001166 · Cited by 44
Self-citationGupta, V., Sehrawat, T. S., Pinzani, M., & Strazzabosco, M. (2024) · Gastroenterology · doi:10.1053/j.gastro.2024.07.044 · Cited by 43
Hirschfield, G. M., Bowlus, C. L., Jones, D. E. J., Kremer, A. E., Mayo, M. J., Tanaka, A., Andreone, P., Jia, J., Jin, Q., Macías-Rodríguez, R. U., et al. (2026) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(25)00192-x · Cited by 34
Self-citationPPAR agonists for the treatment of cholestatic liver diseases: Over a decade of clinical progress
Hayes, C. M., Gallucci, G. M., Boyer, J. L., Assis, D. N., & Ghonem, N. S. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000612 · Cited by 35
Mechanism-guided drug development and treatment for liver fibrosis: a clinical perspective
Zeng, X., Huang, D., Zhu, Z., Cai, Q., Yang, Y., Lu, H., & Chen, J. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1574385 · Cited by 35
Primary Biliary Cholangitis and Primary Sclerosing Cholangitis Therapy Landscape
Bhushan, S. R., Sohal, A., & Kowdley, K. V. (2024) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003174 · Cited by 35
Self-citationCurrent Landscape and Evolving Therapies for Primary Biliary Cholangitis
Fiorucci, S., Urbani, G., Giorgio, C. D., Biagioli, M., & Distrutti, E. (2024) · Cells · doi:10.3390/cells13181580 · Cited by 31
“Consequently, the recommended dosage was determined to be 280 mg/m 2 /4 h.”
BackgroundTrauner, M., Karpen, S. J., & Dawson, P. A. (2025) · Hepatology · doi:10.1097/hep.0000000000001438 · Cited by 32
Drug‐Induced Liver Injury in Patients With Chronic Liver Disease
Ghabril, M., Vuppalanchi, R., & Chalasani, N. (2025) · Liver International · doi:10.1111/liv.70019 · Cited by 30
Epidemiological and economical burden of cholestatic liver disease
Mol, B., Werner, E., Culver, E. L., van der Meer, A. J., Bogaards, J. A., & Ponsioen, C. Y. (2025) · Hepatology · doi:10.1097/hep.0000000000001341 · Cited by 31
Intrahepatic cholestasis of pregnancy
Dajti, E., Tripodi, V. P., Hu, Y., Estiú, M. C., Shan, D., Mazzella, G., & Azzaroli, F. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00633-2 · Cited by 35
“Moreover, it is likely that well-known second-line drugs, such as fibrates 322 and novel drugs such as seladelpar 323 or elafibranor 324 used in other cholestatic diseases, such as PBC, will define the pipeline of novel ICP treatment approaches.”
Guo, Z., He, K., Pang, K., Yang, D., Lyu, C., Xu, H., & Wu, D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084321 · Cited by 30
PPAR Agonists in Primary Biliary Cholangitis
Schnabl, B. (2024) · New England Journal of Medicine · doi:10.1056/nejme2313802 · Cited by 22
European Guideline on Chronic Pruritus. In cooperation with the European Dermatology Forum (EDF)
Weißhaar, E., Müller, S., Szepietowski, J. C., Dalgard, F. J., Garcovich, S., Kupfer, J. P., Giménez‐Arnau, A. M., Lambert, J. R., Mettang, T., Misery, L., et al. (2025) · Acta Dermato Venereologica · doi:10.2340/actadv.v105.44220 · Cited by 38
Global Epidemiology of Primary Biliary Cholangitis: An Updated Systematic Review and Meta-Analysis
Tan, J. J.-R., Chung, A. H.-L., Loo, J. H., Quek, J. W. E., Sharma, S., Singh, C. L., Yap, R. X. J., Tay, W. X., Smith, M. K., Lytvyak, E., et al. (2025) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2025.03.025 · Cited by 42
Levy, C., Trivedi, P. J., Kowdley, K. V., Gordon, S. C., Bowlus, C. L., Londoño, M. C., Hirschfield, G. M., Gulamhusein, A., Lawitz, E. J., Vierling, J. M., et al. (2026) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003603 · Cited by 20
“For RESPONSE results presented here, which include all patients in the placebo-controlled study, responder rate end points were calculated using the intention-to-treat principle; patients with missing data at any time point were considered as nonresponders at that time point (25).”
InfluentialSelf-citationFiorucci, S., Urbani, G., Giorgio, C. D., Biagioli, M., & Distrutti, E. (2024) · Cells · doi:10.3390/cells13191650 · Cited by 26
“PPARs, including the recently approved selective PPARs agonists elafibranor and seladelpar [166,167], that have proven effective in PBC patients are also currently being investigated in PSC. Microbiome modulation offers promising opportunities, especially for PSC patients with concurrent IBD, but…”
Hoy, S. M. (2024) · Drugs · doi:10.1007/s40265-024-02114-4 · Cited by 23
“…and ALT up to 3 × ULN, a total bilirubin up to 2 × ULN and an estimated glomerular filtration rate (eGFR) > 45 mL/min/1.73 m 2 , and had received treatment with UDCA for ≥ 12 months or had a history of unacceptable AEs with UDCA (with their last dose administered > 3 months before screening) [31].”
InfluentialDrugs targeting peroxisome proliferator-activated receptors
Xie, Z., Xin, J., Huang, C.-J., & Liao, C. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104318 · Cited by 25
Cetti, F., Ossoli, A., Garavaglia, C., Dalt, L. D., Norata, G. D., & Gomaraschi, M. (2025) · Annals of Medicine · doi:10.1080/07853890.2025.2497112 · Cited by 19
“Recently, seladelpar met the primary and key secondary endpoints in a Phase 3 study for the treatment of primary biliary cholangitis (PBC) [29].”
Giannini, E. G., Pasta, A., Calabrese, F., Labanca, S., Marenco, S., Pieri, G., Torres, M. C. P., & Strazzabosco, M. (2024) · Liver International · doi:10.1111/liv.16222 · Cited by 21
Game Changers: Blockbuster Small-Molecule Drugs Approved by the FDA in 2024
Wang, Z., Sun, X., Sun, M., Wang, C., & Yang, L. (2025) · Pharmaceuticals · doi:10.3390/ph18050729 · Cited by 18
“The accelerated approval was primarily based on data derived from the placebo-controlled Phase III RESPONSE study, wherein 62% of patients receiving Livdelzi achieved the primary endpoint of composite biochemical response at 12 months compared to only 20% among those on placebo [137].”
Lytvyak, E., Hirschfield, G. M., Shreekumar, D., Wong, Y. J., & Montaño‐Loza, A. J. (2025) · Liver International · doi:10.1111/liv.70190 · Cited by 20
“While changes in LSM over 12 months appeared to be greater with seladelpar than with placebo, there was no significant difference between the two groups [158].”
Self-citationPrimary biliary cholangitis and the narrowing gap towards optimal disease control
Cançado, G. G. L., Lleò, A., Levy, C., Trauner, M., & Hirschfield, G. M. (2025) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(25)00025-1 · Cited by 24
Self-citationGóméz, E., Montero, J. L., Molina, E., García-Buey, L., Casado, M., Fuentes, J., Simón, M. Á., Díaz‐González, Á., Jorquera, F., Morillas, R. M., et al. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.18004 · Cited by 15
“Notably, this augmented response with triple therapy, although the subgroup is only 25% of the whole cohort, maintained statistical significance across all primary endpoints in the multivariate analysis, providing a Phase III trials 28,29 and others in earlier phases of development.”
BackgroundMedical treatment of primary sclerosing cholangitis: What have we learned and where are we going?
Karlsen, T. H., Jørgensen, K. K., & Bergquist, A. M. (2024) · Hepatology · doi:10.1097/hep.0000000000001172 · Cited by 19
Carbone, M., Gerussi, A., Cardinale, V., Cazzagon, N., Cossiga, V., Lleò, A., Marrone, G., Marzioni, M., Moschetta, A., Muratori, L., et al. (2024) · Digestive and Liver Disease · doi:10.1016/j.dld.2024.05.002 · Cited by 18
Saeedian, B., Babajani, N., Bagheri, T., Shirmard, F. O., & Pourfaraji, S. M. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-03821-2 · Cited by 15
“Pruritus was defined differently across studies, such as the Numerical Rating Scale (NRS) ≥ 4 [38, 40, 41] and the Visual Analog Scale (VAS) ≥ 30 [39] or > 0 [37], while some studies did not specify a definition.”
InfluentialClinical management of autoimmune liver diseases: juncture, opportunities, and challenges ahead
Chen, Y., Chen, R., Li, H., & Shuai, Z. (2025) · Immunologic Research · doi:10.1007/s12026-025-09622-9 · Cited by 14
“Fenofibrate acts on PPAR α with a high degree of specificity (NCT00575042) [178, 183], Seladelpar is a specific agonist of PPAR δ [184], Elafibranor is a dual agonist of PPAR α and δ [185], and Saroglitazar is a dual agonist of PPAR α and γ (NCT03112681) [186].”
Wiegand, J., Franke, A., Müller, T., Stein, K., Bantel, H., Günther, R., Denk, G., Reuken, P. A., Schattenberg, J. M., Naumann, U., et al. (2024) · Zeitschrift für Gastroenterologie · doi:10.1055/a-2382-7720 · Cited by 12
Self-citationPeroxisome proliferator–activated receptor delta and liver diseases
Yamazaki, T., Cable, E. E., & Schnabl, B. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000646 · Cited by 16
Breakthrough in the Treatment of Metabolic Associated Steatotic Liver Disease: Is it all over?
Petroni, M. L., Perazza, F., & Marchesini, G. (2024) · Digestive and Liver Disease · doi:10.1016/j.dld.2024.04.021 · Cited by 14
Zhou, H., Huang, Y., Chen, C., Song, M., & Hylemon, P. B. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100120 · Cited by 19
Vincentis, A. D., Ampuero, J., Terracciani, F., D’Amato, D., Gerussi, A., Cristoferi, L., Cazzagon, N., Bonaiuto, E., Floreani, A., Calvaruso, V., et al. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.05.008 · Cited by 13
Self-citationKowdley, K. V., Victor, D. W., MacEwan, J. P., Nair, R., Levine, A., Hernandez, J., Bessonova, L., Li, J., Wheeler, D., & Hirschfield, G. M. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70120 · Cited by 19
Self-citationKomori, A., & Kugiyama, Y. (2024) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0821 · Cited by 14
Bashiri, K., Mattar, M. C., Meighani, A., & Mason, A. L. (2025) · Intestinal Research · doi:10.5217/ir.2025.00090 · Cited by 22
Freer, A., Williams, F. R., Durman, S., Hayden, J. K., Armstrong, M. J., & Trivedi, P. J. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101210 · Cited by 24
The treatment of primary biliary cholangitis: from shadow to light
Dražilová, S., Koky, T., Macej, M., Janíčko, M., Simkova, D., & Jarčuška, P. (2024) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848241265782 · Cited by 16
Barrio, M. D., Díaz‐González, Á., & Alonso‐Peña, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26167905 · Cited by 14
“Plus, Seladelpar also significantly improved pruritus [83–85].”
Sierra, L., Ferrigno, B. W., Marenco‐Flores, A., Alsaqa, M., Rojas, N., Barba, R., Goyes, D., Medina‐Morales, E., Saberi, B., Patwardhan, V. R., et al. (2025) · Annals of Hepatology · doi:10.1016/j.aohep.2025.101945 · Cited by 12
Unmet needs in autoimmune liver diseases
Kolev, M., Kremer, A. E., Sokollik, C., Gershwin, M. E., Beretta‐Piccoli, B. T., Andrade, R. J., Bobzin, C., de Boer, Y. S., de Martin, E., Deganello, A., et al. (2025) · Current Opinion in Immunology · doi:10.1016/j.coi.2025.102565 · Cited by 12
Self-citationVuppalanchi, R., Cruz, M. M., Momin, T., Shaikh, F., Swint, K., Patel, H., & Parmar, D. (2024) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3450 · Cited by 10
Cholestatic liver diseases: modern therapeutics
McNally, B. B., & Carey, E. J. (2025) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2025.2473490 · Cited by 11
Itching for Answers: A Comprehensive Review of Cholestatic Pruritus Treatments
Gabrielli, F., Crepaldi, E., Cavicchioli, A., Rivi, M., Costanzo, A. A. C., Cursaro, C., & Andreoné, P. (2024) · Biomolecules · doi:10.3390/biom14101227 · Cited by 12
Levy, C., Younossi, Z. M., Mayo, M. J., Kremer, A. E., Pate, J., Ieyoub, J., Zincavage, R. M., Padilla, B., Ito, D., & Perez, C. (2025) · Liver International · doi:10.1111/liv.70276 · Cited by 12
Self-citationKoc, O. M., Toussaint, A. C., Untas, A., Milkiewicz, P., Ytting, H., Buck, L., Jones, D. E., Hirschfield, G. M., Leburgue, A., Schramm, C., et al. (2025) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(25)00257-2 · Cited by 19
Self-citationPPAR agonists in PBC: Where do we go from here? Or how to choose between the new and the old
Tanaka, A., & Corpechot, C. (2024) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2024.102358 · Cited by 9
Self-citationAdvancing Second-Line Treatment for Primary Biliary Cholangitis
Assis, D. N. (2024) · New England Journal of Medicine · doi:10.1056/nejme2312745 · Cited by 8
Gelhorn, H. L., Currie, B. M., Bushnell, D. M., Martin, M. L., Fofana, F., Karn, H., Mayo, M. J., Jones, D. E., McLaughlin, M., & von Maltzahn, R. (2025) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-025-03798-x · Cited by 12
Self-citationThe Treatment of Primary Biliary Cholangitis: Time for Personalized Medicine
Men, X., Liu, Y., Zhao, H., Xie, B., Guo, C., Leung, P. S. C., Timilsina, S., Gershwin, M. E., Shang, Y., & Han, Y. (2025) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-025-09074-x · Cited by 15
A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2024
Aksoyalp, Z. Ş., Kayki‐Mutlu, G., Wojnowski, L., & Michel, M. C. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04020-2 · Cited by 11
“It normalizes alkaline phosphatase levels and reduces pruritus (Hirschfield et al. 2024).”
Tana, M. M.-S., & Hirschfield, G. M. (2025) · JAMA · doi:10.1001/jama.2025.20067 · Cited by 11
Self-citationEvaluating the safety and efficacy of seladelpar for adults with primary biliary cholangitis
Caines, A., Trudeau, S., & Gordon, S. C. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2390120 · Cited by 7
“Notably, in the RESPONSE trial there were no meaningful changes in liver stiffness or enhanced liver fibrosis scores observed at month 12 with seladelpar use [42].”
InfluentialYe, K., Yao, X., Lu, D., Tan, C., & Wang, X. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1620073 · Cited by 7
Evolving therapeutic landscape of primary biliary cholangitis: A review
Mitchell, N. E., Chan, S., Diaz, D. J., Ansari, N., Lee, J. S., & Twohig, P. A. (2025) · World Journal of Hepatology · doi:10.4254/wjh.v17.i7.107223 · Cited by 11
Abbas, N., Smith, R. A., Lytvyak, E., Scraravaglio, M., Halliday, N., Almahroos, A., Eden, N., Lloyd‐Madden, D., Sharma, S., Ferguson, J., et al. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70378 · Cited by 9
Self-citationAdvancing the management of primary biliary cholangitis: From pathogenesis to emerging therapies
Curto, A., Iamello, R. G., Lynch, E. N., & Galli, A. (2025) · World Journal of Clinical Cases · doi:10.12998/wjcc.v13.i30.109028 · Cited by 6
Fujinaga, Y., Namisaki, T., Tsuji, Y., Shibamoto, A., Kubo, T., Koizumi, A., Matsuda, T., Inoue, T., Iwai, S., Tomooka, F., et al. (2025) · Hepatology Research · doi:10.1111/hepr.14192 · Cited by 7
“The severity of hepatic fibrosis was reported to predict the development of liver - related complications (LRC) and prognosis in patients with PBC. 5,6 The Scheuer classification is the most widely used histological classification of PBC. 7 However, current staging systems are insufficient to…”
Gannarapu, M. R., Nagiri, R. K., Desagoni, M., & Reddy, V. G. (2025) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266388061250917093142 · Cited by 9
Kowdley, K. V., Ieyoub, J., Pan, Y., Samnaliev, M., Ito, D., & Perez, C. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70391 · Cited by 9
“Beginning in mid-2024, treatment options also include sela-delpar [12] and elafibranor [13].”
Self-citationde Abreu, E. S., Fernandes, G. P., Lacerda, H., Reginato, P. H., Neves, H. A. F., Gonzalez, C. D. S., Eaton, J. E., & Cançado, G. G. L. (2025) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.70094 · Cited by 7
Martins, A., Khakoo, N. S., Reddy, A., Reynolds, J. M., Corpechot, C., Rousseau, A., Murad, M., Sultan, S., & Levy, C. (2025) · Hepatology · doi:10.1097/hep.0000000000001465 · Cited by 12
Self-citationIleal bile acid transporter inhibitors for cholestatic pruritus in primary biliary cholangitis
Lohse, A. W., & Assis, D. N. (2025) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(25)00200-6 · Cited by 6
Considerations in the Diagnoses and Management of Hepatic Disease in Older Adults
Brown, C. L., & Bajaj, J. S. (2025) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003641.07 · Cited by 10
Bezafibrate for primary biliary cholangitis: time to act on the evidence
Corpechot, C., Londoño, M., Villamil, A., Ytting, H., Tanaka, A., & Beuers, U. H. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01135-y · Cited by 8
Self-citationReview of Current and Upcoming Second-Line Treatments for Primary Biliary Cholangitis
Cumpian, N. A., Choi, G., & Saab, S. (2024) · Digestive Diseases and Sciences · doi:10.1007/s10620-024-08742-w · Cited by 6
“Selection criteria for the study included patients intolerant or refractory to UDCA therapy, defined per the Toronto criteria as alkaline phosphatase (ALP) greater than 1.67 times the ULN despite 12 months of UDCA treatment [19].”
InfluentialLevy, C., Jones, D. E. J., Mayo, M. J., Bowlus, C. L., Kowdley, K. V., Hirschfield, G. M., Liu, J., Burk, C., Carroll, S., Crittenden, D. B., et al. (2026) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70630 · Cited by 7
Self-citationVierling, J. M., Hirschfield, G. M., Kustra, R. P., Liu, X., Proehl, S., & Crittenden, D. B. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000845 · Cited by 6
“[4] During RESPONSE, 5 patients (4”
InfluentialSelf-citationJamal, F., Elshaer, A., Alatout, M. H., Odeh, N. B., Youssef, A., Abo Abdullah, H., Elmasry, S., Shahin, T., Abdul Nabi, H., Worden, A. R., et al. (2025) · Biomedicines · doi:10.3390/biomedicines13102335 · Cited by 6
“However, ALT and GGT were significantly decreased with seladelpar which indicates reduced hepatocellular injury [47].”
InfluentialPrimary biliary cholangitis. Treatment options in 2025. A narrative review
Angelara, M., Papachristou, K., Papatheodoridi, Μ., Ansari, N. N., Karagiannakis, D. S., & Ανδρουτσάκος, Θ. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1698833 · Cited by 8
Revisiting PPAR agonists: novel perspectives in the treatment of primary biliary cholangitis
Chen, Y., Zheng, K., Da, G., Wang, X., Wei, Y., Wang, G., Zhang, F., & Wang, L. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2406268 · Cited by 7
Review Article: Targeting Peroxisome Proliferator‐Activated Receptors in Primary Biliary Cholangitis
Schattenberg, J. M., Bañales, J. M., Hirschfield, G. M., Trivedi, P., Cable, E. E., McWherter, C. A., Billin, A. N., Crittenden, D. B., & Budas, G. R. (2026) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70598 · Cited by 5
Self-citationAdvancing care in primary biliary cholangitis: emerging insights and novel therapies
Vögelin, M., & Kremer, A. E. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2516622 · Cited by 5
“The placebo-controlled phase 3 studies ENHANCE and RESPONSE both confirmed a significant reduction in pruritus with seladelpar as early as 1 month of treatment, with the most pronounced effect observed in patients with moderate-to-severe pruritus [15,16,69,70].”
InfluentialSelf-citationde Abreu, E. S., Reginato, P. H., Pitanga, J. F. J., Borges, P. N., Soret, P., Corpechot, C., & Cançado, G. G. L. (2025) · Digestive Diseases and Sciences · doi:10.1007/s10620-025-09044-5 · Cited by 6
“Several new drugs like pemafibrate, elafibranor, and seladelpar, all PPAR agonists, have been recently tested for patients with incomplete response to UDCA, [23–25] with the two latter receiving approval by the United States Food and Drug Administration in 2024.”
Self-citationHepatic Nuclear Receptors in Cholestasis-to-Cholangiocarcinoma Pathology
Cheon, I., Kim, M., Kim, K. H., & Ko, S. (2024) · American Journal Of Pathology · doi:10.1016/j.ajpath.2024.07.023 · Cited by 7
“109,126,127 Similar to other members of the PPAR family, the roles of PPAR d in CCA are generally limited, while there is a publication demonstrating the pro-CCA effect of PPAR d overexpression or its agonist (GW501516) treatment, which promotes the proliferation of human CCA cells.”
Yang, Y., Parfenova, E., Vrdoljak, N., Minden, M. D., Luc, J., Doxey, A. C., & Spagnuolo, P. A. (2025) · Cancer & Metabolism · doi:10.1186/s40170-025-00402-5 · Cited by 6
van Hooff, M. C., de Veer, R. C., Werner, E., Beuers, U. H., Drenth, J. P. H., Cuperus, F. J. C., van Hoek, B., Veldt, B. J., Klemt‐Kropp, M., van Meer, S., et al. (2025) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003879 · Cited by 7
Tanaka, A., Abe, M., Namisaki, T., Shimoda, S., Zeniya, M., Ido, A., Yoshiji, H., Ohira, H., Harada, K., Kakuda, Y., et al. (2025) · Journal of Translational Autoimmunity · doi:10.1016/j.jtauto.2025.100283 · Cited by 5
Shukla, A. K., & Misra, S. (2025) · Journal of Basic and Clinical Physiology and Pharmacology · doi:10.1515/jbcpp-2024-0124 · Cited by 5
Primary biliary cholangitis: current insights and novel therapies
Granito, A., Παππάς, Γ., Napoli, L., Stefanini, B., Tirotta, D., & Muratori, P. (2026) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2026.2672493 · Cited by 9
“Since 2016, the FDA has approved obeticholic acid (OCA), elafibranor, and seladelpar as second-line treatments, specifically for patients who are non-responsive or intolerant to UDCA [34–36].”
InfluentialMeta‐Analysis: PPAR Agonists for Pruritus and Quality of Life in Primary Biliary Cholangitis
Martins, A., Khakoo, N. S., Corpechot, C., Rousseau, A., Reynolds, J. M., Kremer, A. E., Murad, M. H., Sultan, S., & Levy, C. (2026) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70634 · Cited by 5
Self-citationAn update on novel investigational agents for the treatment of primary biliary cholangitis
Floreani, A., Gabbia, D., & Martin, S. D. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2573638 · Cited by 4
“The results of the phase 3 RESPONSE trial (NCT04620733) of seladelpar in PBC patients have been published in February 2024 [38].”
Zaidi, M. H., Haider, Z., Sadia, F., Tayyab, M., Tariq, M., Ans, H., Javaid, M. B., Khan, A., Ahmad, M. H., Rasheed, R., et al. (2025) · JGH Open · doi:10.1002/jgh3.70196 · Cited by 4
Tanaka, A., Treeprasertsuk, S., Chang, M., Tan, S.-S., Efe, C., Jeong, S., Ma, X., Weltman, M., Isayama, H., & Jia, J. (2025) · Hepatology International · doi:10.1007/s12072-025-10965-6 · Cited by 8
“New PPAR agonists, seladelpar and elafibranor, have shown promising results in placebo-controlled clinical trials [60, 61] ( Table 3) and these agents are expected to become available for routine clinical use in the Asia Pacific region.”
Self-citationBile acids as therapeutic agents
Vu, B., Kawamoto, R., Villalba‐Davila, P., Dong, X., & Karnsakul, W. W. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1732854 · Cited by 6
“Bezafibrate (pan-PPAR) is not FDA-approved for PBC but it is used off-label for this condition (Levy et al., 2023; Houri and Hirschfield, 2024; Beuers et al., 2025).”
InfluentialReviewing novel findings and advances in diagnoses and treatment of primary biliary cholangitis
Floreani, A., Gabbia, D., & Martin, S. D. (2025) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2025.2537192 · Cited by 4
“In another phase 3 trial, enrolling 193 patients who had inadequate response or experienced unacceptable side-effects with UDCA, the primary endpoint was set as adequate response to seladelpar treatment according to POISE [62].”
Paik, W. H., Park, J. K., Chung, M. J., Huh, G., Park, C. H., Lee, S. H., Jeong, H. S., Kim, H. J., & Park, D. H. (2024) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0629 · Cited by 10
Progress and prospects of gut microbiota-targeted therapy for primary biliary cholangitis
Tang, X. R., & You, X. (2025) · Gut Pathogens · doi:10.1186/s13099-025-00753-w · Cited by 4
Metadata
- Authors
- Hirschfield, G. M., Bowlus, C. L., Mayo, M. J., Kremer, A. E., Vierling, J. M., Kowdley, K. V., Levy, C., Villamil, A., Ladrón de Guevara Cetina, A. L., Janczewska, E., Zigmond, E., Jeong, S.-H., Yilmaz, Y., Kallis, Y., Corpechot, C., Buggisch, P., Invernizzi, P., Londoño Hurtado, M. C., Bergheanu, S., Yang, K., Choi, Y.-J., Crittenden, D. B., & McWherter, C. A.
- Affiliations
- University Health Network (CA)
- From the Toronto Centre for Liver Disease, Division of Gastroenterology and Hepatology, University Health Network, Toronto General Hospital, Toronto (G.M.H.); the Division of Gastroenterology and Hepatology, University of California Davis School of Medicine, Sacramento (C.L.B.), and CymaBay Therapeutics, Newark (K.Y., Y.-J.C., D.B.C., C.A.M.) — both in California; the University of Texas Southwestern Medical School, Dallas (M.J.M.), and the Departments of Medicine and Surgery, Baylor College of Medicine, Houston (J.M.V.) — both in Texas; the Department of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland (A.E.K.); Liver Institute Northwest, Seattle (K.V.K.); the Division of Digestive Health and Liver Diseases, University of Miami, Miami (C.L.); the Liver Autoimmunity Unit, Hospital Italiano de Buenos Aires, Buenos Aires (A.V.); Centro de Investigación y Gastroenterología, Mexico City (A.L.L.G.C.); the Department of Basic Medical Sciences, Faculty of Publ...
- ORCID
- Hirschfield, Gideon M.
- Bowlus, Christopher L.
- Mayo, Marlyn J.
- Kremer, Andreas E.
- Vierling, John M.
- Kowdley, Kris V.
- Levy, Cynthia
- Villamil, Alejandra
- Janczewska, Ewa
- Zigmond, Ehud
- Jeong, Sook-Hyang
- Yilmaz, Yusuf
- Kallis, Yiannis
- Corpechot, Christophe
- Buggisch, Peter
- Invernizzi, Pietro
- Yang, Ke
- Choi, Yun-Jung
- Crittenden, Daria B.
- McWherter, Charles A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-02-29
- Volume
- 390
- Issue
- 9
- Pages
- 783-794
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4392015136
- Cited by
- 286
- References
- 42
- Citations by year
- 2026: 106 · 2025: 128 · 2024: 52
- FWCI
- 73.92
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- CymaBay Therapeutics
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- seladelpar, primary biliary cirrhosis, PPARδ agonist, ursodeoxycholic acid, biochemical response, alkaline phosphatase, pruritus
- MeSH terms
- Acetates, Administration, Oral, Alkaline Phosphatase, Bilirubin, Cholagogues and Choleretics, Double-Blind Method, Gastrointestinal Agents, Humans, Liver Cirrhosis, Biliary, Pruritus, Ursodeoxycholic Acid, Treatment Outcome, PPAR delta
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.